Palvella Therapeutics, Inc. Proceeds from Issuance of Private Placement
Palvella Therapeutics, Inc. (PVLA) reported Proceeds from Issuance of Private Placement of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-03-31
- Palvella Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2022-12-31 was $0.00.
- Palvella Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2022-09-30 was $0.00.
- Palvella Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. proceeds from issuance of private placement for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Palvella Therapeutics, Inc. proceeds from issuance of private placement for fiscal 2024 was $60.00M.
- Palvella Therapeutics, Inc. proceeds from issuance of private placement for fiscal 2023 was $0.00.
- Palvella Therapeutics, Inc. proceeds from issuance of private placement for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Private Placement 1 month | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-31 | ||||
| 2024-12-31 | $60.00M 10-K · filed 2026-03-31 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $0.00 derived: sum of 2 quarters · filed 2022-11-04 | $0.00 10-Q · filed 2022-11-04 | $0.00 derived: sum of 4 quarters · filed 2023-03-31 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | $0.00 derived: sum of 4 quarters · filed 2023-03-31 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | $9.24M derived: sum of 4 quarters · filed 2023-03-31 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $9.24M derived: sum of 3 quarters · filed 2023-03-31 | $18.91M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $9.24M derived: sum of 2 quarters · filed 2022-11-04 | $18.91M 10-Q · filed 2022-11-04 | $18.91M derived: sum of 4 quarters · filed 2022-11-04 | |
| 2021-06-30 | $9.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $18.91M 10-Q · filed 2022-08-04 | $18.91M derived: sum of 3 quarters · filed 2022-08-04 | $18.91M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $9.67M 10-Q · filed 2022-05-11 | $9.67M derived: sum of 2 quarters · filed 2022-05-11 | $9.67M derived: sum of 3 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $0.00 derived: sum of 2 quarters · filed 2022-03-02 | $0.00 10-K · filed 2022-03-02 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $0.00 10-Q · filed 2021-11-02 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | ||||
| 2016-06-30 | $16.50M 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |